NYSE:GKOS
Glaukos Corporation Stock News
$107.98
+2.97 (+2.83%)
At Close: May 07, 2024
Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3
07:00am, Wednesday, 13'th Jul 2022
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
03:09pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
12:48pm, Wednesday, 08'th Jun 2022
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
10:20am, Thursday, 02'nd Jun 2022 Zacks Investment Research
Smart Beta ETF report for XHE
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
10:20am, Wednesday, 11'th May 2022 Zacks Investment Research
Sector ETF report for XHE
Glaukos (GKOS) Stock Falls 25.9% Despite Q1 Earnings Beat
03:04pm, Tuesday, 10'th May 2022 Zacks Investment Research
Glaukos' (GKOS) soft Q1 results fail to impress investors.
Glaukos (GKOS) Stock Falls 25.9% Despite Q1 Earnings Beat
12:48pm, Tuesday, 10'th May 2022
Glaukos' (GKOS) soft Q1 results fail to impress investors.
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
10:45pm, Wednesday, 04'th May 2022 Zacks Investment Research
Glaukos (GKOS) delivered earnings and revenue surprises of 26.92% and 11.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
08:18pm, Wednesday, 04'th May 2022
Glaukos (GKOS) delivered earnings and revenue surprises of 26.92% and 11.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Glaukos Corporation (GKOS) CEO Tom Burns on Q1 2022 Results - Earnings Call Transcript
07:48pm, Wednesday, 04'th May 2022
Glaukos Corporation (NYSE:GKOS ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Tom Burns – Chairman & Chief Executive Officer Joe Gilliam – President & Chief Operati
Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
07:00am, Wednesday, 13'th Apr 2022
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
03:33pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos begins phase 2 program for 3rd gen iLink therapy to treat eye disorder keratoconus
01:47pm, Monday, 14'th Mar 2022 Seeking Alpha
Glaukos Corporation (GKOS) said it had begun a Phase 2 clinical trial to test its third generation therapy, iLink, to treat keratoconus, a thinning disorder of the…
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
04:07pm, Wednesday, 23'rd Feb 2022 Zacks Investment Research
Despite reporting a fourth-quarter loss, Glaukos' (GKOS) results reflect a noticeable rise in revenues.
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
12:20pm, Wednesday, 23'rd Feb 2022
Despite reporting a fourth-quarter loss, Glaukos' (GKOS) results reflect a noticeable rise in revenues.
